Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Trials
Published in: Trials 1/2019

Open Access 01-12-2019 | Kidney Transplantation | Study protocol

PRODIG (Prevention of new onset diabetes after transplantation by a short term treatment of Vildagliptin in the early renal post-transplant period) study: study protocol for a randomized controlled study

Authors: E. Gaiffe, T. Crepin, J. Bamoulid, C. Courivaud, M. Büchler, E. Cassuto, L. Albano, J. M. Chemouny, G. Choukroun, M. Hazzan, L. Kessler, C. Legendre, Y. Le Meur, N. Ouali, A. Thierry, A. Anota, V. Nerich, S. Limat, F. Bonnetain, D. Vernerey, D. Ducloux

Published in: Trials | Issue 1/2019

Login to get access

Abstract

Background

Post-transplant diabetes is a frequent and serious complication of kidney transplantation. There is currently no treatment to prevent or delay the disease. Nevertheless, identification of risk factors make it possible to target a population at risk of developing de novo diabetes. We hypothesized that a short-term treatment with vildagliptin may prevent new onset diabetes after transplantation (NODAT) in high-risk patients.

Methods/design

This is a multicenter, double-blind, placebo-controlled randomized clinical trial. Patients undergoing first kidney transplantation will be included from ten French transplant centers. Included patients will be randomized (1:1) to receive either vildagliptin 100 or 50 mg/day (depending on glomerular filtration rate) during 2 months (the first dose being administered before entering the operating theatres) or placebo. Additional antidiabetic therapy could be administered according to glycemic control. The primary outcome is the proportion of diabetic patients 1 year after transplantation, defined as patients receiving a diabetic treatment, or having a fasting glucose above 7 mmol/l, and/or with an abnormal oral glucose tolerance test. Secondary outcomes include glycated hemoglobin, the occurrence of acute rejection, infection, graft loss and patient death at 3 months, 6 months, and 12 months after transplantation. Outcomes will be correlated to clinical and general characteristics of the patient, cardiovascular history, nephropathy, dialysis history, transplantation data, biological data, health-related quality of life, and the cost-effectiveness of prevention of diabetes with vildagliptin.

Discussion

We have scarce data on the pharmacological prevention of post-transplant diabetes. If our hypothesis is verified, our results will have a direct application in clinical practice and could limit diabetes-associated morbidity, reduce cardiovascular complications, increase quality of life of renal transplant patients, and consequently promote graft and patient survival. Our results may possibly serve for non-transplant patients carrying a high-risk of diabetes associated with other co-morbidities.

Trial registration

ClinicalTrials.gov, NCT02849899. Registered on 8 February 2016.
Appendix
Available only for authorised users
Literature
1.
Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant. 2003;3(2):178–85.PubMedCrossRef
2.
Cosio FG, Pesavento TE, Kim S, Osei K, Henry M, Ferguson RM. Patient survival after renal transplantation: IV. Impact of post-transplant diabetes. Kidney Int. 2002;62(4):1440–6.PubMedCrossRef
3.
Ducloux D, Kazory A, Chalopin J-M. Posttransplant diabetes mellitus and atherosclerotic events in renal transplant recipients: a prospective study. Transplantation. 2005;79(4):438–43.PubMedCrossRef
4.
Chakkera HA, Weil EJ, Swanson CM, Dueck AC, Heilman RL, Reddy KS, et al. Pretransplant risk score for new-onset diabetes after kidney transplantation. Diabetes Care. 2011;34(10):2141–5.PubMedPubMedCentralCrossRef
5.
Chakkera HA, Chang Y-H, Ayub A, Gonwa TA, Weil EJ, Knowler WC. Validation of a pretransplant risk score for new-onset diabetes after kidney transplantation. Diabetes Care. 2013;36(10):2881–6.PubMedPubMedCentralCrossRef
6.
Hecking M, Haidinger M, Döller D, Werzowa J, Tura A, Zhang J, et al. Early basal insulin therapy decreases new-onset diabetes after renal transplantation. J Am Soc Nephrol JASN. 2012;23(4):739–49.PubMedCrossRef
7.
Brubaker PL, Drucker DJ. Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology. 2004;145(6):2653–9.PubMedCrossRef
8.
Rangel EB. Tacrolimus in pancreas transplant: a focus on toxicity, diabetogenic effect and drug-drug interactions. Expert Opin Drug Metab Toxicol. 2014;10(11):1585–605.PubMedCrossRef
9.
Zhong J, Rao X, Rajagopalan S. An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: potential implications in cardiovascular disease. Atherosclerosis. 2013;226(2):305–14.PubMedCrossRef
10.
Bamoulid J, Courivaud C, Deschamps M, Mercier P, Ferrand C, Penfornis A, et al. IL-6 promoter polymorphism −174 is associated with new-onset diabetes after transplantation. J Am Soc Nephrol JASN. 2006;17(8):2333–40.PubMedCrossRef
11.
Haidinger M, Werzowa J, Hecking M, Antlanger M, Stemer G, Pleiner J, et al. Efficacy and safety of vildagliptin in new-onset diabetes after kidney transplantation--a randomized, double-blind, placebo-controlled trial. Am J Transplant. 2014;14(1):115–23.PubMedCrossRef
12.
Werzowa J, Hecking M, Haidinger M, Lechner F, Döller D, Pacini G, et al. Vildagliptin and pioglitazone in patients with impaired glucose tolerance after kidney transplantation: a randomized, placebo-controlled clinical trial. Transplantation. 2013;95(3):456–62.PubMedCrossRef
13.
Anota A, Hamidou Z, Paget-Bailly S, Chibaudel B, Bascoul-Mollevi C, Auquier P, et al. Time to health-related quality of life score deterioration as a modality of longitudinal analysis for health-related quality of life studies in oncology: do we need RECIST for quality of life to achieve standardization? Qual Life Res. 2015;24(1):5–18.PubMedCrossRef
14.
Bonnetain F, Dahan L, Maillard E, Ychou M, Mitry E, Hammel P, et al. Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma. Eur J Cancer Oxf Engl. 2010;46(15):2753–62.CrossRef
15.
16.
Courivaud C, Ladrière M, Toupance O, Caillard S, Hurault de Ligny B, Ryckelynck J-P, et al. Impact of pre-transplant dialysis modality on post-transplant diabetes mellitus after kidney transplantation. Clin Transplant. 2011;25(5):794–9.PubMedCrossRef
17.
18.
Avramovic M, Stefanovic V. Health-related quality of life in different stages of renal failure. Artif Organs. 2012;36(7):581–9.PubMedCrossRef
19.
Wyld M, Morton RL, Hayen A, Howard K, Webster AC. A systematic review and meta-analysis of utility-based quality of life in chronic kidney disease treatments. PLoS Med. 2012;9(9):e1001307.PubMedPubMedCentralCrossRef
20.
21.
Haines TP, Sinnamon P, Wetzig NG, Lehman M, Walpole E, Pratt T, et al. Multimodal exercise improves quality of life of women being treated for breast cancer, but at what cost? Randomized trial with economic evaluation. Breast Cancer Res Treat. 2010;124(1):163–75.PubMedCrossRef
22.
Parkin D, Devlin N. Is there a case for using visual analogue scale valuations in cost-utility analysis? Health Econ. 2006;15(7):653–64.PubMedCrossRef
23.
Landreneau K, Lee K, Landreneau MD. Quality of life in patients undergoing hemodialysis and renal transplantation--a meta-analytic review. Nephrol Nurs J. 2010;37(1):37–44.PubMed
24.
Purnell TS, Auguste P, Crews DC, Lamprea-Montealegre J, Olufade T, Greer R, et al. Comparison of life participation activities among adults treated by hemodialysis, peritoneal dialysis, and kidney transplantation: a systematic review. Am J Kidney Dis. 2013;62(5):953–73.PubMedCrossRef
25.
Barendse S, Singh H, Frier BM, Speight J. The impact of hypoglycaemia on quality of life and related patient-reported outcomes in Type 2 diabetes: a narrative review. Diabet Med. 2012;29(3):293–302.PubMedCrossRef
26.
Landman GWD, van Hateren KJJ, Kleefstra N, Groenier KH, Gans ROB, Bilo HJG. Health-related quality of life and mortality in a general and elderly population of patients with type 2 diabetes (ZODIAC-18). Diabetes Care. 2010;33(11):2378–82.PubMedPubMedCentralCrossRef
27.
Kizilisik AT, Feurer ID, VanBuren DH, Wise P, Van Buren D, Hopkins J, et al. Effects of diabetes and cadaveric organs on functional performance and health-related quality of life after kidney transplantation. Am J Surg. 2003;186(5):535–9.PubMedCrossRef
28.
Gentile S, Jouve E, Dussol B, Moal V, Berland Y, Sambuc R. Development and validation of a French patient-based health-related quality of life instrument in kidney transplant: the ReTransQoL. Health Qual Life Outcomes. 2008;6:78.PubMedPubMedCentralCrossRef
29.
Beauger D, Gentile S, Jouve E, Dussol B, Jacquelinet C, Briançon S. Analysis, evaluation and adaptation of the ReTransQoL: a specific quality of life questionnaire for renal transplant recipients. Health Qual Life Outcomes. 2013;11:148.PubMedPubMedCentralCrossRef
30.
Chevalier J, de Pouvourville G. Valuing EQ-5D using time trade-off in France. Eur J Health Econ. 2013;14(1):57–66.PubMedCrossRef
31.
Roborel de Climens A, Tunceli K, Arnould B, Germain N, Iglay K, Norquist J, et al. Review of patient-reported outcome instruments measuring health-related quality of life and satisfaction in patients with type 2 diabetes treated with oral therapy. Curr Med Res Opin. 2015;31(4):643–65.PubMedCrossRef
32.
Woodward RS, Schnitzler MA, Baty J, Lowell JA, Lopez-Rocafort L, Haider S, et al. Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. Am J Transplant. 2003;3(5):590–8.PubMedCrossRef
33.
Stoumpos S, Jardine AG, Mark PB. Cardiovascular morbidity and mortality after kidney transplantation. Transpl Int. 2015;28(1):10–21.PubMedCrossRef
34.
ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–72.CrossRef
Metadata
Title
PRODIG (Prevention of new onset diabetes after transplantation by a short term treatment of Vildagliptin in the early renal post-transplant period) study: study protocol for a randomized controlled study
Authors
E. Gaiffe
T. Crepin
J. Bamoulid
C. Courivaud
M. Büchler
E. Cassuto
L. Albano
J. M. Chemouny
G. Choukroun
M. Hazzan
L. Kessler
C. Legendre
Y. Le Meur
N. Ouali
A. Thierry
A. Anota
V. Nerich
S. Limat
F. Bonnetain
D. Vernerey
D. Ducloux
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Trials / Issue 1/2019
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-019-3392-6

Other articles of this Issue 1/2019

Trials 1/2019 Go to the issue

Study protocol

Preoperative CT versus intraoperative hybrid DynaCT imaging for localization of small pulmonary nodules: a randomized controlled trial

Study protocol

A study protocol for a randomised controlled trial evaluating the effects of intraoperative computed tomography on the outcomes of zygomatic fractures

Study protocol

Effects of inclined treadmill training on functional and cardiovascular parameters of stroke patients: study protocol for a randomized controlled trial

Study protocol

Efficacy and safety of Hou Gu Mi Xi in patients with spleen qi deficiency syndrome who underwent radical gastrectomy for gastric cancer: protocol for a multicenter, randomized, double-blind, placebo-controlled trial

Research

Opportunities for selective reporting of harms in randomized clinical trials: Selection criteria for non-systematic adverse events

Study protocol

Effect of multi-lumen perfusion line on catheter-related bacteremia in premature infants: study protocol for a cluster-randomized crossover trial